Recognizing Anticholinergic Burden in HIV Care

Modern antiretroviral therapy has extended longevity, yet older individuals face emerging geriatric syndromes. Multimorbidity frequently leads clinicians to prescribe multiple chronic therapies. Consequently, healthcare providers observe an alarming rise in anticholinergic burden in HIV cohorts across outpatient settings. Anticholinergic medications block muscarinic acetylcholine receptors throughout central and peripheral tissues. Many non-antiretroviral drugs exhibit unintended anticholinergic activity, including tricyclic antidepressants, first-generation antihistamines, bladder antispasmodics, and antipsychotics. In addition, cardiovascular medications like certain beta-blockers and diuretics contribute low-level cumulative properties. When patients take several such drugs concurrently, their cumulative exposure expands exponentially. Furthermore, chronic neuroinflammation and prior immunosuppression sensitize the central nervous system to cholinergic blockade. Therefore, people living with HIV demonstrate greater vulnerability to adverse effects than age-matched uninfected peers. Routine clinical reviews frequently fail to identify these exposures because individual agents appear relatively harmless in isolation. However, the compound impact impairs central neurotransmission and undermines physiological stability. Clinicians must acknowledge this escalating pharmacological threat during every routine consultation. Early identification of high-risk prescriptions enables proactive intervention before irreversible functional deterioration occurs. Similarly, educating patients about over-the-counter sleep aids prevents unexpected toxicities. This vigilance maintains cognitive resilience over time.

Clinical Impact on Cognition, Frailty, and Falls

Elevated anticholinergic exposure produces profound physiological consequences across multiple organ systems. Observational research links high anticholinergic scores to sharp decrements in neuropsychological performance. Specifically, patients experience impaired processing speed, reduced attention span, and compromised executive functioning. Advanced neuroimaging studies even demonstrate accelerated brain atrophy and compromised white matter integrity in vulnerable individuals. In addition, peripheral anticholinergic manifestations cause severe patient discomfort and secondary morbidity. Clinicians regularly detect dry mouth, severe constipation, blurred vision, and acute urinary retention. These symptoms frequently trigger prescribing cascades when physicians mistake drug side effects for new medical pathologies. Furthermore, peripheral neuromuscular deficits combine with central sedation to degrade physical balance. Consequently, affected individuals suffer recurrent falls, traumatic fractures, and sudden hospital admissions. Frailty indices rise steeply among older patients with prior advanced immunodeficiency or past opportunistic infections. Sedative co-medications further amplify these risks by compounding central nervous system depression. Thus, unmonitored drug toxicity rapidly erodes independent living and diminishes general quality of life. Clinicians must systematically connect non-specific geriatric complaints to the patient's existing medication list. Proactive reviews safeguard physical vitality and preserve autonomy.

Comparing Measurement Tools and Antiretroviral Interactions

Clinicians utilize several standardized scales to quantify cumulative medication risk in clinical practice. Popular scoring systems include the Anticholinergic Cognitive Burden scale, the Anticholinergic Risk Scale, and the Anticholinergic Drug Scale. However, each instrument evaluates distinct drug subsets, which leads to substantial scoring discrepancies during case finding. For example, some tools overlook milder agents, whereas other indices assign differing risk weights to cardiovascular therapies. In addition, researchers frequently recommend the Drug Burden Index when patients consume concurrent sedatives. This dose-aware model accounts for prescribed daily quantities alongside intrinsic receptor affinity. Meanwhile, clinicians must evaluate crucial pharmacokinetic drug-drug interactions between chronic comedications and antiretroviral regimens. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors heavily influence cytochrome P450 pathways. Specifically, pharmacologically boosted regimens containing ritonavir or cobicistat substantially increase systemic exposure to psychotropic and anticholinergic agents. Therefore, an otherwise modest dose of amitriptyline or quetiapine can achieve toxic plasma concentrations rapidly. Similarly, renal clearance alterations and hepatic changes demand vigilant therapeutic adjustments. Pharmacists and physicians must navigate verified databases, such as the Liverpool Drug Interaction Checker, before finalizing any therapeutic regimen. Integrating these assessment methods provides a reliable foundation for tailored clinical interventions.

A Pragmatic Stewardship Algorithm for Clinical Practice

Implementing a structured stewardship algorithm streamlines medication management within busy ambulatory clinics. First, healthcare teams must perform comprehensive medication reconciliation at every routine appointment. This process captures over-the-counter sleep aids, herbal remedies, and prescriptions from external subspecialists. Next, clinicians calculate a baseline exposure score using an established anticholinergic scale. If the patient takes concurrent sedatives, the clinician calculates the cumulative Drug Burden Index. Subsequently, providers screen for targeted clinical syndromes, including gait instability, frequent falls, progressive memory decline, and chronic constipation. Once the team confirms meaningful medication toxicity, they prioritize candidates for deprescribing or dosage reduction. Clinicians should eliminate unnecessary agents that lack clear ongoing indications. Furthermore, prescribers must select safer alternatives that possess minimal muscarinic antagonist activity. For instance, clinicians can replace sedating first-generation antihistamines with second-generation alternatives like cetirizine or fexofenadine. Likewise, selective serotonin reuptake inhibitors with low anticholinergic action can replace tricyclic antidepressants for mood disorders. However, clinicians must taper psychoactive drugs slowly to prevent distressing withdrawal phenomena or symptom recurrence. Clear documentation and patient engagement ensure high adherence throughout this therapeutic transition. Continuous follow-up guarantees sustained clinical safety.

Overcoming Implementation Challenges in Diverse Health Settings

Translating medication stewardship into routine practice requires overcoming distinct logistical barriers across different healthcare systems. Large academic hospitals frequently employ dedicated clinical pharmacists who manage polypharmacy consultations effectively. In contrast, peripheral clinics and centers in low-resource environments often face severe workforce constraints and high patient volumes. Clinicians in these settings rarely possess automated electronic health record alerts to flag cumulative anticholinergic burden. Consequently, busy providers may overlook dangerous drug interactions during brief, focused clinical encounters. To bridge this gap, health authorities must develop concise, pocket-sized screening algorithms and simplified mobile applications. Moreover, multidisciplinary task sharing can empower trained nursing personnel to complete preliminary medication reconciliation. Infectious disease physicians must also collaborate closely with primary care providers, geriatricians, and local chemists. Community health programs should educate patients regarding the risks of self-medicating with over-the-counter sedative-hypnotics. In addition, prospective implementation trials are urgently required to establish cost-effectiveness and quantify clinical benefits on fall prevention and cognition. Standardizing these stewardship practices will safeguard vulnerable ageing individuals across diverse clinical environments. Ultimately, proactive medication surveillance ensures that the hard-won survival gains of modern antiretroviral therapy translate into healthy ageing.

Why are aging people living with HIV more susceptible to anticholinergic side effects?

Aging people living with HIV demonstrate heightened vulnerability because chronic neuroinflammation and viral persistence compromise the blood-brain barrier. Furthermore, long-term immunodeficiency reduces central cholinergic receptor density and diminishes neurocognitive reserve. When physicians add medications possessing muscarinic antagonism, these central changes exacerbate susceptibility to toxic insults. Consequently, affected patients experience accelerated cognitive decline and severe executive dysfunction. Moreover, they suffer frequent postural imbalance and recurrent traumatic falls compared to uninfected peers.

Which common medications contribute most frequently to cumulative anticholinergic burden?

Numerous therapeutic classes contribute unintended anticholinergic activity beyond classical antispasmodics. First-generation antihistamines, including diphenhydramine and hydroxyzine, exhibit profound muscarinic receptor blockade. In addition, tricyclic antidepressants like amitriptyline and antipsychotics like olanzapine generate substantial central anticholinergic effects. Even standard gastrointestinal therapies and bladder relaxants like oxybutynin add significant potency. Furthermore, cardiovascular medications such as furosemide and atenolol exert low-level cumulative properties. Therefore, taking several mild agents concurrently produces severe additive clinical toxicity across vulnerable populations.

How should clinicians safely deprescribe anticholinergic agents in antiretroviral-treated patients?

Clinicians must execute deprescribing systematically rather than discontinuing multiple medications abruptly. First, providers should identify target drugs that lack clear clinical indications or cause obvious adverse symptoms. Next, prescribers substitute offending medications with modern alternatives that exhibit minimal cholinergic affinity. For example, clinicians can exchange tricyclic agents for selective serotonin reuptake inhibitors. Furthermore, physicians must taper psychoactive therapies slowly over several weeks to avoid rebound cholinergic toxicity or withdrawal syndromes. Finally, scheduling regular follow-up visits ensures lasting symptom control and sustained clinical recovery.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Mazzitelli M et al. HIV and anticholinergic burden: Towards a pragmatic stewardship algorithm. Br J Clin Pharmacol. 2026 Sep 09. doi: 10.1002/bcp.70811. PMID: 42716913.


2. Mazzitelli M, Trunfio M, Leoni D, et al. Anticholinergic burden interacts with age and AIDS history to amplify frailty in people with HIV. Br J Clin Pharmacol. 2026; doi:10.1002/bcp.70504.


3. Doctor J, Michael HU, Underwood J, et al. Anticholinergic and sedative medication use in persons with HIV: Defining the evidence for risks on cognition. J Antimicrob Chemother. 2024;79(9):2163-2169.